Former Chief Operating Officer · Spero Therapeutics, Inc. (SPRO)

Cristina Larkin

A named executive officer of Spero Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,903,930

Salary $460,406Stock awards $399,994

FY2018: $533,799

3rd of 3 named executive officers at Spero Therapeutics by FY2021 total.

3 named officers on file for Spero Therapeutics, FY2021

Cristina Larkin’s pay file — $29

  • 3 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Spero Therapeutics’s whole pay program stands against its peers

  • Spero Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed August 5, 2022 (DEF 14A).

Free

Get Cristina Larkin’s full pay file as a PDF — free

More than this page: up to 10 years of Cristina’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Cristina Larkin compensation by year

Spero Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Spero Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2021
Salary$330,669$385,000$460,406
Bonus$0$0$0
Stock awards$0$0$399,994
Option awards$796,800$0$848,983
Non-equity incentive$98,325$148,225$185,107
Pension and deferred compensation$0$0$0
All other$734$574$9,440
Total$1,226,528$533,799$1,903,930

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spero Therapeutics, Inc. DEF 14A filed August 5, 2022, accession 0001193125-22-213583, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Spero Therapeutics, Inc. filed document, accession 0001193125-22-213583. Every figure is read from that document and cited to the page and table it appears in. Filed August 5, 2022.

$1.2M
$534K
$1.9M
FY17
FY18
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU24,067$399,994—
Option29,792—$9.34
Option17,604—$6.26
Option57,432—$19.18

Per the Outstanding Equity Awards at Fiscal Year-End table in Spero Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Spero Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Ankit MahadeviaChief Executive Officer$4,875,045
Satyavrat ShuklaChief Financial Officer$2,228,271
Cristina Larkin · this pageFormer Chief Operating Officer$1,903,930

The full Spero Therapeutics compensation record

free company brief

This page is one person within Spero Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Cristina Larkin's compensation dossier · One-time report. No refunds.